HanAll Biopharma Launches Topical Hair Loss Treatment 'Pangro Solution 5%'

Available in a 200 mL size
Includes a dispensing container for added convenience

HanAll Biopharma said on October 8 that it has launched Pangro Solution 5%, a topical minoxidil-based hair loss treatment, to expand the options available for managing hair loss.

Product image of HanAll Biopharma's topical hair loss treatment, Pangro Solution 5%. HanAll Biopharma

Pangro Solution 5% is an over-the-counter medicine containing minoxidil, used to treat male-pattern hair loss (androgenetic alopecia), and is applied directly to the scalp. It comes in a 200 mL size and includes a spray-type dispensing container that lets users dispense as much as needed, making it more convenient to use.

With this launch, HanAll Biopharma now offers a full range of key hair loss treatment ingredients and formulations: Hairgro tablets, a finasteride product; Adamo tablets and Adamo soft capsules, dutasteride products; Pangro capsules, an adjunctive hair loss treatment; and Pangro Solution 5%, a topical product applied directly to the scalp.

Since 2022, HanAll Biopharma has designated hair loss as one of its key business areas and continued to expand its business in the field. That year, it established a dedicated production line for hair loss treatments at its Daejeon plant and introduced a fully automated system and a closed manufacturing process, enhancing production efficiency and quality control capabilities.

HanAll Biopharma plans to continue expanding its share of the hair loss treatment market, drawing on a product lineup that includes both oral and topical medicines. “We have steadily built a foundation for our hair loss treatment business with a dedicated production line and a diverse product portfolio,” said Park Sujin, CEO of HanAll Biopharma. “With this launch, we will further strengthen our position as a pharmaceutical company specializing in hair loss treatments.”

This content was produced with the assistance of AI translation services.